Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048.

Semrad, Thomas J; Groshen, Susan; Luo, Chunqiao; Pal, Sumanta; Vaishampayan, Ulka; Joshi, Monika; Quinn, David I; Mack, Philip C; Gandara, David R; Lara, Primo N

Semrad, Thomas J; Groshen, Susan; Luo, Chunqiao; Pal, Sumanta; Vaishampayan, Ulka; Joshi, Monika; Quinn, David I; Mack, Philip C; Gandara, David R; Lara, Primo N.

Afiliación

Semrad TJ; Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, CA, USA.
Groshen S; University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Luo C; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Pal S; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Vaishampayan U; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Joshi M; Karmanos Cancer Institute, Detroit, MI, USA.
Quinn DI; Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Mack PC; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Gandara DR; University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Lara PN; University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA.

Kidney Cancer ; 3(1): 51-61, 2019 Feb 05.

Article en En | MEDLINE | ID: mdl-30854497

Palabras clave

Renal cell carcinoma; angiopoietin; trebananib; vascular endothelial growth factor

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Kidney Cancer Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google